1
|
Song GY, Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Leuk Lymphoma 2020; 61:2714-2721. [PMID: 32580672 DOI: 10.1080/10428194.2020.1783448] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.
Collapse
Affiliation(s)
- Ga-Young Song
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
| | - Sung-Hoon Jung
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
| | - Je-Jung Lee
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
| | - Jin Seok Kim
- Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Chang-Ki Min
- Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea
| | - Kihyun Kim
- Samsung Medical Center, Seoul, Republic of Korea
| | - Yunsuk Choi
- Ulsan University Hospital, Ulsan, Republic of Korea
| | | | - Young Don Joo
- Inje University Busan Paik Hospital, Busan, Republic of Korea
| | | | - Jae-Yong Kwak
- Chonbuk National University Medical School, Jeonju, Republic of Korea
| | - Hye Jin Kang
- Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| | - Jae Hoon Lee
- Gachon University Gil Hospital, Incheon, Republic of Korea
| | - Ho Sup Lee
- Kosin University Gospel Hospital, Busan, Republic of Korea
| | - Yeung-Chul Mun
- Ewha Woman's University School of Medicine, Seoul, Republic of Korea
| | - Joon Ho Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - Sang Kyun Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - Seong Kyu Park
- Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea
| | - Yong Park
- Korea University College of Medicine, Seoul, Republic of Korea
| | - Ho-Jin Shin
- Pusan National University Hospital, Busan, Republic of Korea
| | - Sung-Soo Yoon
- Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
2
|
Lee JY, Lee SM, Choi MY, Kim KH, Joo YD, Im SN, Lee WS. Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas. Blood Res 2016; 51:187-192. [PMID: 27722130 PMCID: PMC5054251 DOI: 10.5045/br.2016.51.3.187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 06/26/2016] [Accepted: 08/02/2016] [Indexed: 11/17/2022] Open
Abstract
Background This study aimed to assess the treatment outcomes of ifosphamide, mesna, etoposide, and prednisolone (IMEP) combination regimen as a front-line chemotherapy in patients with peripheral T-cell lymphomas (PTCLs). Methods Clinical data of 38 newly diagnosed PTCLs patients who underwent IMEP at Busan Paik Hospital from January 2002 to December 2013 were retrospectively analyzed. Results The overall response rate was 68.5%, with 21 (55.3%) complete response/complete response unconfirmed and 6 (15.8%) partial response (PR). The median follow-up duration was 25.5 months (range, 0.2-87.3). The median overall survival was not reached and 2-year survival rate was 67%. The median progression free survival was 23 months. The most frequently reported adverse effects higher than grade 3 were hematologic toxicities including neutropenia (68.4%), thrombocytopenia (42.1%). There was no treatment-related mortality. Conclusion IMEP regimen is effective and safe as a front-line chemotherapy in patients with PTCLs.
Collapse
Affiliation(s)
- Ji Young Lee
- Department of Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Sang Min Lee
- Department of Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Moon Young Choi
- Department of Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Ki Hyang Kim
- Department of Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Young Don Joo
- Department of Internal Medicine, Hemato-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea
| | - Sung Nam Im
- Department of Internal Medicine, Hemato-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea
| | - Won Sik Lee
- Department of Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| |
Collapse
|
3
|
Seol YM, Kim HJ, Choi YJ, Lee EM, Kim YS, Oh SY, Koh SJ, Baek JH, Lee WS, Joo YD, Lee HG, Yun EY, Chung JS. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer 2015; 24:945-952. [PMID: 26265119 DOI: 10.1007/s00520-015-2865-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 07/27/2015] [Indexed: 11/26/2022]
Abstract
BACKGROUND Palonosetron is the second-generation 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA) that has shown better efficacy than the first-generation 5-HT3RA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC). Granisetron transdermal delivery system (GTDS), a novel transdermal formulation, was developed to deliver granisetron continuously over 7 days. This study compared the efficacy and tolerability of the GTDS to palonosetron for the control of CINV following MEC. MATERIAL AND METHOD A total of 196 patients were randomized to GP or PG group. In this multicenter, randomized, open-label, cross-over, active-controlled, Phase IV study, GP group was assigned to receive transdermal granisetron (one GTDS patch, 7 days) in the first chemotherapy cycle, palonosetron (iv 0.25 mg/day, 1 days) in the second chemotherapy cycle before receiving MEC, and PG group was assigned to receive palonosetron in the first cycle and GTDS in the second cycle. Primary endpoint was the percentage of chemotherapy cycles achieving complete response (CR; defined as no emetic episodes and no rescue medication use) during the acute phase (0-24 h in post-chemotherapy; non-inferiority comparison with palonosetron). RESULTS Total 333 cycles (165 in GTDS and 168 in palonosetron) were included in the per protocol analysis. The GTDS cycles showed non-inferiority to palonosetron cycles during the acute phase: CR was achieved by 124 (75.2 %) patients in the GTDS cycles and 134 (79.8 %) patients in the palonosetron cycles (treatment difference, -4.6 %; 95 % confidence interval, -13.6-4.4). There was no significant difference in CR rate during acute phase after the end of the first and second chemotherapy cycle between GP and PG group (p = 0.405, p = 0.074). Patients' satisfaction, assessed using Functional Living Index-Emesis (FLI-E), GTDS cycle were higher than those of palonosetron cycle in GP group (FLI-E score; median 1549.5 in GTDS cycle, median 1670.0 in palonosetron cycle). Both treatments were well tolerated and safe. CONCLUSION Transdermal granisetron is a good alternative therapeutic option to palonosetron for preventing CINV after MEC.
Collapse
Affiliation(s)
- Young Mi Seol
- Division of Hemato-Oncology, Department of Internal Medicine, Pusan National University Hospital Medical Research Institute, 1-10 Ami-Dong, Seo-Gu, Busan, 602-739, South Korea
| | - Hyo Jeong Kim
- Division of Hemato-Oncology, Department of Internal Medicine, Pusan National University Hospital Medical Research Institute, 1-10 Ami-Dong, Seo-Gu, Busan, 602-739, South Korea
| | - Young Jin Choi
- Division of Hemato-Oncology, Department of Internal Medicine, Pusan National University Hospital Medical Research Institute, 1-10 Ami-Dong, Seo-Gu, Busan, 602-739, South Korea
| | - Eun Mi Lee
- Division of Hemato-Oncology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea
| | - Yang Soo Kim
- Division of Hemato-Oncology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea
| | - Sung Yong Oh
- Division of Hemato-Oncology, Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, South Korea
| | - Su Jin Koh
- Division of Hemato-Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
| | - Jin Ho Baek
- Division of Hemato-Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
| | - Won Sik Lee
- Division of Hemato-Oncology, Department of Internal Medicine, Inje University Paik Hospital, Inje University College of Medicine, Busan, South Korea
| | - Young Don Joo
- Division of Hemato-Oncology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea
| | - Hyun Gi Lee
- Department of Biostatistician, Pusan National University Hospital Medical Research Institute, Busan, South Korea
| | - Eun Young Yun
- Department of Biostatistician, Pusan National University Hospital Medical Research Institute, Busan, South Korea
| | - Joo Seop Chung
- Division of Hemato-Oncology, Department of Internal Medicine, Pusan National University Hospital Medical Research Institute, 1-10 Ami-Dong, Seo-Gu, Busan, 602-739, South Korea.
| |
Collapse
|
4
|
Ahn JS, Yang DH, Jung SH, Lee JJ, Kim I, Park S, Chung JS, Shin HJ, Kim DY, Lee KH, Moon JH, Sohn SK, Song IC, Jo DY, Joo YD. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. Acta Haematol 2014; 133:91-7. [PMID: 25171064 DOI: 10.1159/000362261] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Accepted: 03/14/2014] [Indexed: 11/19/2022]
Abstract
Mitoxantrone is a conventional agent for relapsed or refractory acute lymphoblastic leukemia (ALL). However, an effective combination with other drugs and a feasible dosage has not been identified. A retrospective study of 46 patients with relapsed or refractory ALL was conducted to determine the efficacy of mitoxantrone and Ara-C treatment with (MEC) and or without etoposide (MC). Twenty-seven and 19 patients received MC and MEC chemotherapy, respectively. Twenty-two (48%) patients showed overall response [complete response (CR), 33%; CR with incomplete platelet recovery (CRp), 15%], and 10 of 22 responders received allogeneic stem cell transplantation (SCT). Median overall survival (OS) was 6.2 months (95% confidence interval, 3.41-9.0). Thirteen (48%) patients in the MC group and 9 (47%) in the MEC group achieved CR/CRp (p = 0.96). Treatment-related mortalities in the MC and MEC groups were 3 (11%) and 4 (21%), respectively (p = 0.36). However, the MEC group frequently presented with grade 3 or higher bacteremia/candidemia (p = 0.013). No difference in OS was observed between the two groups (p = 0.769). In conclusion, salvage therapy consisting of mitoxantrone and Ara-C without etoposide appeared to be an effective bridge therapy to allogeneic SCT for patients with refractory or relapsed ALL.
Collapse
Affiliation(s)
- Jae-Sook Ahn
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University, Hwasun, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kim DY, Moon JH, Joo YD. Current status and future directions of clinical research and practice in adult acute lymphoblastic leukemia patients in Korea. Blood Res 2014; 49:80-2. [PMID: 25025006 PMCID: PMC4090340 DOI: 10.5045/br.2014.49.2.80] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- Dae-Young Kim
- Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Joon Ho Moon
- Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea
| | - Young Don Joo
- Inje University Haeundae-Paik Hospital, Busan, Korea
| |
Collapse
|
6
|
Kim H, Lee KH, Kim I, Sohn SK, Jung CW, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Kim MK, Bae SH, Shin HJ, Won JH, Lee WS, Oh S, Kim HJ, Park JH. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG. Leuk Res 2014; 38:730-6. [PMID: 24840870 DOI: 10.1016/j.leukres.2014.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 12/23/2013] [Accepted: 01/02/2014] [Indexed: 11/19/2022]
Abstract
Total body irradiation (TBI) has traditionally been used in the conditioning regimen for allogenetic hematopoietic stem cell transplantation (alloHCT) from an unrelated donor (u-HCT). However, patients are increasingly receiving a fludarabine-based conditioning regimen without TBI, as it seemed less toxic than TBI. We need to know the clinical results of non-TBI u-HCT treatments. We retrospectively investigated the clinical outcomes of allogenetic hematopoietic cell transplantation (alloHCT) from an unrelated donor without TBI (non-TBI u-HCT) and compared the clinical outcomes of fludarabine-based (FLU group) and cyclophosphamide-ATG (Cy-ATG group) conditioning regimens. Sixty-one patients received the non-TBI conditioning regimen for u-HCT (32 in the FLU group and 29 in the Cy-ATG group). The cumulative incidence of neutrophil engraftment at 30 days, platelet>20K/μL at 30 days, acute graft-versus host disease (aGvHD) at 100 days, and chronic GvHD (cGvHD) at 2 years were 87.01%, 65.57%, 35.20%, and 26.64%, respectively. However, transplantation outcomes and overall survival rates did not differ between the FLU and Cy-ATG groups. Only infused CD34+ cells >3×10(6)kg(-1) was identified as a favorable factor for survival in the multivariate analysis. In conclusion, non-TBI u-HCT was feasible and there was no difference between the FLU and Cy-ATG groups in terms of transplantation outcomes.
Collapse
Affiliation(s)
- Hawk Kim
- Ulsan University Hospital, 877 Baneojinsunwhan-doro, Ulsan, Republic of Korea.
| | - Kyoo-Hyung Lee
- Asan Medical Center, 86 Asanbyeongwon-gil, Seoul, Republic of Korea
| | - Inho Kim
- Seoul National University Hospital, 101 Daehang-ro, Seoul, Republic of Korea
| | - Sang Kyun Sohn
- Kyungpook National University Hospital, 135, Dongdeok-ro, Daegu, Republic of Korea
| | - Chul Won Jung
- Samsung Medical Center, 50 Irwon-dong, Gangnam-gu, Seoul, Republic of Korea
| | - Young Don Joo
- Inje University Haeundae Paik Hospital, 875 Haeundae-ro, Busan, Republic of Korea
| | - Sung-Hyun Kim
- Dong-A University Medical Center, 26 Daesingongwon-ro, Busan, Republic of Korea
| | - Byung Soo Kim
- Korea University Hospital Seoul Hospital, 73 Inchon-ro, Seoul, Republic of Korea
| | - Jung Hye Choi
- Hanyang University Hospital, 222 Wangsimni-ro, Seoul, Republic of Korea
| | - Jae-Yong Kwak
- Chonbuk National University Hospital, 20 Geonji-ro, Jeonju-si, Jeollabuk-do, Republic of Korea
| | - Min Kyoung Kim
- Yeungnam University Medical Center, 170 Hyeonchung-ro, Daegu, Republic of Korea
| | - Sung Hwa Bae
- Daegu Catholic University Hospital, 33 Duryugongwon-ro 17-gil, Daegu, Republic of Korea
| | - Ho Jin Shin
- Pusan National University Hospital, 179 Gudeok-ro, Busan, Republic of Korea
| | - Jong-Ho Won
- Soonchunhyang University Seoul Hospital, 59 Dassagwan-ro, Seoul, Republic of Korea
| | - Won Sik Lee
- Inje University Busan Paik Hospital, 75 Bokji-ro, Busan, Republic of Korea
| | - Sukjoong Oh
- Kangbuk Samsung Hospital, 29 Saemunan-ro, Seoul, Republic of Korea
| | - Hyo Jung Kim
- Hallym University Sacred Heart Hospital, Hallym University Medical Center, Anyang, Republic of Korea.
| | - Jae-Hoo Park
- Ulsan University Hospital, 877 Baneojinsunwhan-doro, Ulsan, Republic of Korea.
| |
Collapse
|
7
|
Ahn SY, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ann Hematol 2014; 93:1571-7. [PMID: 24728664 DOI: 10.1007/s00277-014-2067-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2014] [Accepted: 03/18/2014] [Indexed: 10/25/2022]
Abstract
This phase II study prospectively evaluated the efficacy and tolerability of an early change in induction therapy before autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients who failed to achieve more than a partial response (PR) after two cycles of a cyclophosphamide, thalidomide, and dexamethasone (CTD) regimen. Patients aged 18-65 years received two cycles of CTD therapy, and then the patients who achieved more than a PR received two additional cycles of CTD therapy, while those who failed to achieve more than a PR were given intensified therapy with four cycles of a Vel-CD regimen (bortezomib, cyclophosphamide, and dexamethasone). After completing primary chemotherapy, the patients underwent ASCT. This study initially enrolled 64 patients, although four were excluded. Of the patients, 60 were treated with CTD regimen and 8 patients also had the intensified Vel-CD regimen, of whom five showing improved responses. The overall response rate before ASCT in 59 patients was 94.9 %, including 27.1 % with a stringent complete response/complete response, 23.7 % with a very good partial response (VGPR), and 44.1 % with a PR. The median time to progression (TTP) was 33.2 months (95 % CI, 26.6-34.8). Patients who attained a VGPR or better after ASCT tended to have a longer TTP than the patients who did not (not reached vs. 24.2 months, P = 0.04). In conclusion, early response-adapted intensification with a Vel-CD regimen was a well-tolerated, effective strategy for improving the response before ASCT in patients with newly diagnosed MM.
Collapse
Affiliation(s)
- Seo-Yeon Ahn
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kim H, Lee KH, Sohn SK, Jung CW, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Kim MK, Bae SH, Shin HJ, Won JH, Oh S, Lee WS, Park JH, Yoon SS. Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia. Leuk Res 2013; 37:1241-7. [PMID: 23871157 DOI: 10.1016/j.leukres.2013.06.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2013] [Revised: 06/04/2013] [Accepted: 06/17/2013] [Indexed: 01/20/2023]
Abstract
We retrospectively investigated the incidence, risk factors, and outcomes of SOS (sinusoidal obstruction syndrome; previously veno-occlusive disease [VOD]) after allogeneic hematopoietic stem cell transplantation (alloHSCT) in aplastic anemia. Two hundred and sixty patients were included in the analysis. SOS developed in 7.3% (n=19/260) of patients. Classical Cy (200 mg/m(2))-ATG was the most common conditioning regimen (84.2%) in the SOS group. The SOS mortality rate was 4/19 (21.1%). Univariate analyses revealed that Cy 200 mg/m(2) conditioning (p=0.035), classical Cy-ATG conditioning (p=0.007), and horse ATG conditioning (p<0.001) were significant risk factors for developing SOS. Multivariate analysis revealed that only horse ATG conditioning was a poor prognostic factor (HR=3.484; 95% CI 1.226-9.904; p=0.002). Rabbit ATG (HR 12.719; 95% CI 2.332-69.373; p=0.003) and weight gain>10% (HR 35.655; 95% CI 2.208-575.805; p=0.012) were risk factors in the overall SOS group. Both rabbit ATG conditioning and weight gain of more than 10% were associated with poor overall survival with a median of 1.2 months (5Y survival rate, any risk factor vs. none: 74.6% vs. 0.0%; p<0.001; Fig. 2) in the SOS group. In conclusion, SOS is a relatively rare (7.3%) but highly fatal (21.1%) acute complication of alloHSCT in AA, and the horse ATG conditioning regimen was a significant risk factor for developing SOS.
Collapse
Affiliation(s)
- Hawk Kim
- Divison of Hematology and Hematological Malignancies, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Yi HG, Kim JS, Suh C, Kim WS, Kwak JY, Lee JS, Kim YS, Joo YD, Min YH, Lee HG, Yoon SS, Won JH, Park S, Kim HC, Kim CS. Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. Blood Res 2013; 48:115-20. [PMID: 23826580 PMCID: PMC3698396 DOI: 10.5045/br.2013.48.2.115] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2012] [Revised: 02/09/2013] [Accepted: 05/17/2013] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. METHODS In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. RESULTS Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration. CONCLUSION The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.
Collapse
Affiliation(s)
- Hyeon Gyu Yi
- Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea. ; Korean Society of Hematology Lymphoma Working Party, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kim I, Koh Y, Yoon SS, Park S, Kim BK, Kim DY, Lee JH, Lee KH, Cheong JW, Lee HK, Kim SH, Kim H, Joo YD, Lee SM, Won JH, Park SK, Hong DS, Kim SH, Sohn SK, Kim CS, Park E, Kim MK, Park MR, Lee JH, Min YH. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. Am J Hematol 2013; 88:10-5. [PMID: 23077109 DOI: 10.1002/ajh.23337] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2011] [Revised: 08/29/2012] [Accepted: 08/30/2012] [Indexed: 12/11/2022]
Abstract
We performed a phase II trial to evaluate the efficacy and safety of the modified fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) regimen in elderly acute myeloid leukemia (AML) patients. Elderly (≥60 years) AML patients who had not previously received chemotherapy were enrolled in the study. Patients received two consecutive cycles of m-FLAI chemotherapy as an induction. The m-FLAI regimen comprised fludarabine (25 mg/m(2) , days 1-4), cytarabine (1,000 mg/m(2) , days 1-4), and attenuated-dose idarubicin (5 mg/m(2) , days 1-3). The primary end point was complete remission (CR) rate. Secondary end points were overall survival (OS), event-free survival (EFS), and treatment-related mortality (TRM). There were 108 patients (median age 68.4 years, M:F = 64:44) enrolled in the study. CR was achieved in 56.5% of patients, and the TRM rate was 21.3%. Median OS and median EFS were 10.2 and 6.6 months, respectively. The mortality at 30 and 60 days was 15 and 21%, respectively. Performance status and comorbidity did not have prognostic value in this patient cohort. Bone marrow expression of CD117 was associated with increased EFS and OS. m-FLAI is an effective induction regimen for previously untreated AML in elderly patients. In addition, bone-marrow CD117 expression is an independent favorable prognostic factor in elderly AML patients. (ClinicalTrials.gov number, NCT01247493).
Collapse
Affiliation(s)
- Inho Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kim H, Lee KH, Yoon SS, Sohn SK, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Hyun MS, Bae SH, Shin HJ, Won JH, Oh S, Lee WS, Park JH, Jung CW. Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia. Biol Blood Marrow Transplant 2012; 18:1500-8. [PMID: 22472480 DOI: 10.1016/j.bbmt.2012.03.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Accepted: 03/22/2012] [Indexed: 11/29/2022]
Abstract
Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.
Collapse
Affiliation(s)
- Hawk Kim
- Ulsan University Hospital, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kim H, Kim BS, Kim DH, Hyun MS, Kim SH, Bae SH, Choi JH, Sohn SK, Shin HJ, Won JH, Yoon SS, Jo DY, Joo YD, Park JH, Lee KH. Comparison between Matched Related and Alternative Donors of Allogeneic Hematopoietic Stem Cells Transplanted into Adult Patients with Acquired Aplastic Anemia: Multivariate and Propensity Score-Matched Analysis. Biol Blood Marrow Transplant 2011; 17:1289-98. [DOI: 10.1016/j.bbmt.2010.12.715] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Accepted: 12/30/2010] [Indexed: 10/18/2022]
|
13
|
Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 2011; 52:1024-9. [DOI: 10.3109/10428194.2011.563885] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
14
|
Koh Y, Kim DY, Park SH, Jung SH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Shin HJ, Kim SH, Song HS, Chung J, Kim I, Yoon SS, Kim BK, Shin SH, Chung YJ, Park S. GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. ACTA ACUST UNITED AC 2010; 203:215-21. [DOI: 10.1016/j.cancergencyto.2010.08.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2010] [Revised: 08/12/2010] [Accepted: 08/23/2010] [Indexed: 11/24/2022]
|
15
|
Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010; 95:1935-42. [PMID: 20663943 DOI: 10.3324/haematol.2010.026104] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be effective in steroid-refractory, chronic graft-versus-host disease. However, most of the data were from small numbers of patients or retrospective analyses. We, therefore, conducted a multicenter phase II study to confirm the efficacy of this treatment strategy that targets B cells. DESIGN AND METHODS We diagnosed and evaluated chronic graft-versus-host disease according to the National Institute of Health criteria for clinical trials on this condition. The treatment consisted of weekly intravenous infusions of rituximab for 4 weeks followed by monthly rituximab for 4 months. We evaluated the patients' responses and monitored their disease activity until their final visit, which was on day 365. We also assessed the patients' subsequent quality of life and serum levels of B-cell-activating factor of the tumor necrosis factor family. RESULTS Among 37 patients enrolled (median age, 29 years; range 8-57 years), 32 patients responded to rituximab with 8 complete and 24 partial responses. Twenty-one patients maintained their response for 1 year, so their steroid treatment was discontinued or its dose reduced (21/37, or 56.8%), and their scores representing quality of life were improved although these changes were not statistically significant. The responses were better for clinical manifestations of the skin, oral cavity and musculoskeletal system (response rate, 71.4-100%) than for other organs. However, infectious complications and primary disease relapse accounted for the majority of treatment failure. The pre-treatment serum level of B cell-activating factor of the tumor necrosis factor family was not associated with better treatment outcome (P=0.147). CONCLUSIONS Rituximab could improve clinical responses and quality of life of patients with steroid-refractory chronic graft-versus-host disease, although such patients may need active prophylaxis against infection.
Collapse
Affiliation(s)
- Seok Jin Kim
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann Hematol 2010; 89:725-31. [PMID: 20179930 DOI: 10.1007/s00277-010-0910-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2009] [Accepted: 01/27/2010] [Indexed: 10/19/2022]
Abstract
The aim of this phase IV study was to (1) to define efficacy of escalating dose imatinib in chronic myeloid leukemia (CML) patients showing suboptimal response to standard dose imatinib and (2) to find markers that predict the response to escalating doses of imatinib. CML patients in chronic phase (CP) who failed to achieve optimal response with 400 mg/day imatinib or patients in accelerated phase (AP) or blast crisis (BC) who failed to achieve complete hematologic response after 3 months of 400-600 mg/day imatinib were enrolled. CP patients received 600 mg/day, while AP/BC patients received 600-800 mg/day imatinib. Patients received imatinib for at least 12 months or until the disease progression or intolerable toxicity. Along with cytogenetic response (CyR), molecular response was assessed with BCR-ABL/ABL ratio. Baseline BCR-ABL gene mutation test was performed. Seventy-one patients (median age, 49.0 years, M:F = 50:21) received escalated dose imatinib. Grade 3 edema in two patients was the only nonhematologic toxicities more than grade 2. For evaluable patients, 30.8% of patients achieved CCyR at 6 months, and median time to treatment failure (TTFx) was 18.0 months. TTFx was longer in patients who achieved greater than 50% reduction in BCR-ABL/ABL within 6 months (early molecular responder (EMR)) compared with those who did not (non-EMR; p < 0.001). Of 31 patients who had mutational status data, three had mutation. All mutants failed to achieve CCyR. In conclusion, escalated dose imatinib shows considerable efficacy with tolerable toxicity in CML patients showing suboptimal response to standard dose imatinib. EMR is an early predictive marker for positive imatinib response.
Collapse
Affiliation(s)
- Youngil Koh
- Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Jongno-gu, Seoul 110-744, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Lee JY, Joo YD, Oh SH, Shin JH, Kim HR, Lee SM, Lee JN. Prognostic Significance of FLT3 Internal Tandem Duplication in Acute Myeloid Leukemia with Normal Karyotype. Korean J Hematol 2009. [DOI: 10.5045/kjh.2009.44.2.74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Ja Young Lee
- Department of Laboratory Medicine, Inje University College of Medicine, Busan, Korea
| | - Young Don Joo
- Department of Internal Medicine, Inje University College of Medicine, Busan, Korea
| | - Seung Hwan Oh
- Department of Laboratory Medicine, Inje University College of Medicine, Busan, Korea
| | - Jeong Hwan Shin
- Department of Laboratory Medicine, Inje University College of Medicine, Busan, Korea
- Paik Institute for Clinical Research, Inje University College of Medicine, Busan, Korea
| | - Hye Ran Kim
- Department of Laboratory Medicine, Inje University College of Medicine, Busan, Korea
| | - Sang Min Lee
- Department of Internal Medicine, Inje University College of Medicine, Busan, Korea
| | - Jeong Nyeo Lee
- Department of Laboratory Medicine, Inje University College of Medicine, Busan, Korea
- Paik Institute for Clinical Research, Inje University College of Medicine, Busan, Korea
| |
Collapse
|
18
|
Lee SM, Kwon MJ, Kang MJ, Lee EJ, Lee WS, Sohn CH, Lee JY, Lee JN, Kim H, Joo YD. Factors to Predict Autologous CD34 Positive Cells Harvest in the Patients with Malignant Lymphoproliferative Disorder. Korean J Hematol 2009. [DOI: 10.5045/kjh.2009.44.1.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Sang Min Lee
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Min-Jeong Kwon
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Myung Joo Kang
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Eun Joo Lee
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Won Sik Lee
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Chang Hak Sohn
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Ja Young Lee
- Department of Labatory Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Jeong Nyeo Lee
- Department of Labatory Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Hawk Kim
- Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
| | - Young Don Joo
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| |
Collapse
|
19
|
Lee SM, Kim KH, Kang MJ, Choi MY, Lee WS, Joo YD. Hodgkin's Lymphoma-like Posttransplantation Lymphoproliferative Disorder after Allogeneic Hematopoietic Stem Cell Transplantation. Korean J Hematol 2009. [DOI: 10.5045/kjh.2009.44.4.278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Sang Min Lee
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Ki Hyang Kim
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Myung Joo Kang
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Moon Young Choi
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Won Sik Lee
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| | - Young Don Joo
- Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
| |
Collapse
|
20
|
Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, Yang DH, Kim HJ, Kim JG, Joo YD, Lee WS, Sohn CH, Lee EY, Cho GJ. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci 2008; 23:439-44. [PMID: 18583880 PMCID: PMC2526520 DOI: 10.3346/jkms.2008.23.3.439] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The objective of the current study was to investigate the treatment outcomes for the use of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) chemotherapy in adult patients with hemophagocytic lymphohistiocytosis (HLH). Seventeen HLH patients older than 18 yr of age were treated with CHOP chemotherapy. A response evaluation was conducted for every two cycles of chemotherapy. With CHOP chemotherapy, complete response was achieved for 7/17 patients (41.2%), a partial response for 3/17 patients (17.6%), and the overall response rate was 58.8%. The median response duration (RD) was not reached and the 2-yr RD rate was 68.6%, with a median follow-up of 100 weeks. Median overall survival (OS) was 18 weeks (95% CI, 6-30 weeks) and the 2-yr OS rate was 43.9%. Reported grade 3 or 4 non-hematological toxicities were increased serum liver enzyme levels and stomatitis. Grade 3 or 4 hematological toxicities were leukopenia (50.8%), anemia (20%), and thrombocytopenia (33.9%). Neutropenic fever was observed in 21.6% of patients (14/65 cycles), and most of the cases were resolved with supportive care including treatment with broad-spectrum antibiotics. CHOP chemotherapy seems to be effective in adult HLH patients and the toxicities are manageable.
Collapse
Affiliation(s)
- Ho-Jin Shin
- Department of Hematology-Oncology, Pusan National University Medical School, Pusan National University Hospital, Busan, Korea
| | - Joo Seop Chung
- Department of Hematology-Oncology, Pusan National University Medical School, Pusan National University Hospital, Busan, Korea
| | - Je-Jung Lee
- Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju; Chonnam National University Hwasun Hospital, Hwasun, Korea
| | - Sang Kyun Sohn
- Department of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Korea
| | - Young Jin Choi
- Department of Hematology-Oncology, Pusan National University Medical School, Pusan National University Hospital, Busan, Korea
| | - Yeo-Kyeoung Kim
- Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju; Chonnam National University Hwasun Hospital, Hwasun, Korea
| | - Deok-Hwan Yang
- Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju; Chonnam National University Hwasun Hospital, Hwasun, Korea
| | - Hyeoung-Joon Kim
- Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju; Chonnam National University Hwasun Hospital, Hwasun, Korea
| | - Jong Gwang Kim
- Department of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Korea
| | - Young Don Joo
- Department of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Won Sik Lee
- Department of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Chang-Hak Sohn
- Department of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Korea
| | - Eun Yup Lee
- Department of Clinical Pathology, College of Medicine, Pusan National University, Busan, Korea
| | - Goon Jae Cho
- Department of Hematology-Oncology, Pusan National University Medical School, Pusan National University Hospital, Busan, Korea
| |
Collapse
|
21
|
Lee JY, Kim JH, Shin JH, Kim HR, Lee JN, Kim KH, Lee WS, Joo YD, Sohn CH, Kim CH. Primary Isolated Bone Marrow Diffuse Large B-cell Lymphoma with Hemolytic Anemia as the First Manifestation. Korean J Hematol 2008. [DOI: 10.5045/kjh.2008.43.1.48] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Ja Young Lee
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Jae Hyun Kim
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Jeong Hwan Shin
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Hye Ran Kim
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Jeong Nyeo Lee
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Ki Hyang Kim
- Department of Hemato-oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Won Sik Lee
- Department of Hemato-oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Young Don Joo
- Department of Hemato-oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Chang Hak Sohn
- Department of Hemato-oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| | - Chan-Hwan Kim
- Department of Pathology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea
| |
Collapse
|
22
|
Seol YM, Kwon BR, Choi YJ, Lee KW, Shin HJ, Chung JS, Lee EY, Lee WS, Joo YD, Cho GJ. The Efficacy and Adverse Effect of Hydroxyurea as Compared with Anagrelide in Essential Thrombocythemia. Korean J Hematol 2008. [DOI: 10.5045/kjh.2008.43.2.83] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Young Mi Seol
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Bo Ran Kwon
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Young Jin Choi
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Kyung Woo Lee
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Ho Jin Shin
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Joo Seop Chung
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Eun Yup Lee
- Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Korea
| | - Won Sik Lee
- Department of Internal Medicine, Inje University College of Medicine, Busan, Korea
| | - Young Don Joo
- Department of Internal Medicine, Inje University College of Medicine, Busan, Korea
| | - Goon Jae Cho
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
| |
Collapse
|
23
|
Affiliation(s)
- Jeong Nyeo Lee
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Busan, Korea
- Paik Institute for Clinical Research, Inje University, Busan, Korea
| | - Hye Ran Kim
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Busan, Korea
| | - Jeong Hwan Shin
- Department of Laboratory Medicine, Busan Paik Hospital, College of Medicine, Busan, Korea
- Paik Institute for Clinical Research, Inje University, Busan, Korea
| | - Young Don Joo
- Department of Internal Medine, Busan Paik Hospital, College of Medicine, Busan, Korea
| |
Collapse
|
24
|
Joo YD, Lee WS, Kim JL, Yang JW, Kim HW, Park SK, Sohn CH. A Case of Invasive Maxillary and Orbital Aspergillosis Inhematopoietic Stem Cell Transplantation Recipient with Severe Aplastic Anemia. Korean J Hematol 2005. [DOI: 10.5045/kjh.2005.40.3.205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Young Don Joo
- Department of Internal Medicine, College of Medicine, Inje University, Busan, Korea
| | - Won Sik Lee
- Department of Internal Medicine, College of Medicine, Inje University, Busan, Korea
| | - Jung Lim Kim
- Department of Ophthalmology, College of Medicine, Inje University, Busan, Korea
| | - Jae Wook Yang
- Department of Ophthalmology, College of Medicine, Inje University, Busan, Korea
| | - Hyun Woong Kim
- Department of Ophthalmology, College of Medicine, Inje University, Busan, Korea
| | - Seong Kook Park
- Department of Otorhinolaryngology, College of Medicine, Inje University, Busan, Korea
| | - Chang Hak Sohn
- Department of Internal Medicine, College of Medicine, Inje University, Busan, Korea
| |
Collapse
|
25
|
Cho KI, Kim DS, Kim TI, Park JH, Kim SM, Kim DK, Kim DI, Joo YD. Echocardiographic Assessment of LV Geometric Pattern and Function in Pregnancy-Induced Hypertension. Korean Circ J 2005. [DOI: 10.4070/kcj.2005.35.10.718] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Affiliation(s)
- Kyoung Im Cho
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Dong Soo Kim
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Tae Ik Kim
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Jeong Ho Park
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Sung Man Kim
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Dae Kyeong Kim
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Doo Il Kim
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| | - Young Don Joo
- Division of Cardiology, Maryknoll General Hospital, Busan, Korea
| |
Collapse
|
26
|
Joo YD, Sohn CH. Clinical Significance of p53, P-glycoprotein, and Glutathione S transferase-pi in Advanced Non-Small Cell Lung Cancer. Cancer Res Treat 2002; 34:34-40. [PMID: 26680840 DOI: 10.4143/crt.2002.34.1.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE A retrospective study was performed o define the clninical significance of p53, P-glycoprotein (Pgp), and Glutathione S transferase-pi (GST-pi) immunohistochemical (IHC) expression in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS We reviewed fifty seven patients with advanced NSCLC who had undergone surgical resection or bronchoscopic biopsy between March 1997 and March 1999. IHC staining for p53, GST-pi, and Pgp was performed using formalin-fixed, paraffin-embedded specimens of the fifty seven patients. RESULTS The IHC expression rate was 63% for p53, 28% for Pgp, and 53% for GST-pi, respectively. The median survival of the fifty seven patients was 45 weeks and the response rate was 38.6% (partial response, 22/57). The chemotherapy response and median survival of the p53 negative group (57% and 61 weeks) were better than those demonstrated by the p53 positive group (28% and 21 weeks) (p<0.05). Additionally, the GST-pi negative group showed a greater improvement of survival and response rate than the positive group (p<0.05). Pgp expression status appeared to have no significant differential effect on chemotherapy response and survival. CONCLUSION These results suggest that immunohisto chemical staining of p53 and GST-pi may be useful in predicting the response to chemotherapy as well as survival in advanced NSCLC. However, this study is limited by its retrospective nature and the small numbers of tumors studied from a heterogenous group of patients.
Collapse
|
27
|
Joo YD, Lee IH, Kim DS, Lee KS. Clinical Effects of Doxazosin in Essential Hypertension. Korean Circ J 1991. [DOI: 10.4070/kcj.1991.21.4.745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
28
|
Harrison AM, Joo YD, Israel JR. Intra-arterial administration of oral pentazocine. JAMA 1970; 214:914. [PMID: 5535952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|